Amyloid-[beta]-lowering agent fails to slow Alzheimer's in phase III trial.
CHICACO -- Tarenflubil, a drug designed to reduce toxic amyloid [beta] levels in the brains of Alzheimer's disease patients, failed its large phase III trial, Dr. Robert Green reported at the International Conference on Alzheimer's Disease. Patients who received the drug (800 mg twice daily) had virtually...

Alzheimer's markers.
[ILLUSTRATION OMITTED] This A-beta peptide fibril has been rendered in 3-D by a transmission electron microscope, providing the most detailed look yet at the telltale sign of Alzheimer's disease. While we still do not know just how Alzheimer's progresses or what role the fibrils play, they are...

Alternative Alzheimer's drug research.
Geneva-based pharmaceutical company Anavex Life Sciences is currently testing a drug created in response to an alternative theory about what causes Alzheimer's disease. According to press materials from the company, in recent decades, researchers seeking a drug to treat the underlying cause of Alzheimer's have focused their...

Insulin linked with decreased brain plaques in Alzheimer's.
CHICAGO -- A postmortem analysis of subjects with both Alzheimer's disease and diabetes found up to 80% fewer amyloid [beta] plaques in the brains of those who took both insulin and oral diabetic medication while alive. The finding might shed some light on a discrepancy that has...

Marital status at midlife linked to Alzheimer's risk later.
CHICAGO -- People who are married from mid-to late life are significantly less likely to develop Alzheimer's disease, while those who remain single face up to an eightfold increased risk, Krister Hakansson said at the International Conference on Alzheimer's Disease. The protective benefit is probably related to...

Peter Davies, Ph.D. Gets Lifetime Achievement Award from Alzheimer's Association.
HEALTH AND BEAUTY CLOSE-UP-31 July 2008-Peter Davies, Ph.D. Gets Lifetime Achievement Award from Alzheimer's Association(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Applied NeuroSolutions, a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease (AD), announced its founding scientist, Dr. Peter Davies,...

Type 2 diabetes doesn't affect Alzheimer's risk.
WASHINGTON -- Type 2 diabetes did not increase the risk of onset or progression of Alzheimer's disease in older adults, according to results from a study of more than 700 individuals presented in a poster at the annual meeting of the American Geriatrics Society. The prevalences of...

Blood test in pipeline may help diagnose Alzheimer's.
CHICAGO -- A simple blood test could soon allow primary care providers to diagnose Alzheimer's disease accurately if a final validation study proceeds as well as optimistic researchers hope. In a study of 88 patients, the test findings agreed with expert clinical diagnosis more than 90%, with...

Late-life low blood pressure associated with Alzheimer's.
WASHINGTON--Low blood pressure correlated with Alzheimer's disease among 3,734 elderly men, but the dementia appeared to be attributable to the presence of other chronic diseases and not hypotension itself. Other studies have found that hypertension in midlife can predict dementia, but the impact of late-life blood pressure...

Alzheimer's sixth leading death cause.
Alzheimer's disease is now the sixth leading cause of death in the United States, ending about 72,900 American lives in 2006, according to recent data from the National Center for Health Statistics. As many as 5.2 million Americans are living with the disease, with a report from...